Recent developments in HIV protease inhibitor therapy

Antiviral Research

Volumn 39, Issue 1, 1998, Pages 1-23

  Molla, Akhteruzzaman ^a   Richard Granneman, G ^a   Sun, Eugene ^a   Kempf, Dale J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antiviral; Genotypic patterns in resistance; HIV therapy; Protease inhibitors; Resistance

Indexed keywords

1 (3 AMINO 5 INDAZOLYL) 4,7 DIBENZYL 3 BUTYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 2H 1,3 DIAZEPIN 2 ONE; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDINAVIR; LOPINAVIR; MOZENAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CROSS RESISTANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MUTANT; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032128592     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00011-4     Document Type: Article

References (98)

1. Acosta, E.P., Henry, K., Weller, D., Page, L.M., Bacon, L., Rhame, F., Gilson, I., Rosenstein, H., Schacker, T., Fletcher, C.V., 1997. Indinavir pharmacokinetics and relationship between exposure and antiviral effect. 37th ICAAC, Abstract A-15, Toronto, Canada.
2. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., Katalaba C., Debre P., Leibowitch J. Positive effects of combined antiretroviral therapy on CD+ T cell homeostasis and function in advanced HIV disease. Science. 277:1998;112-116.
3. Bacheler, L.T., Rodgers, J.D., Lam, P.Y.S., Wright, M., Garber, S., Reid, C., Erickson-Viitanen, S., 1997. New cyclic urea-based protease inhibitors with improved potency, oral bioavailability and resistance profiles. Abstract-2, Sixth International Workshop on HIV drug resistance, treatment strategies and eradication, St. Petersburg, Florida.
4. Borin, M.T., Wang, Y., Schneck, D.W., Li, H., Brewer, J.E., Daenzer, C.L., 1998. Multi-dose safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections. Abstract 648, IL.
5. ™): pharmacokinetics and drug interactions. 5th conference on retroviruses and opportunistic infections. Abstract 354, IL.
6. Cameron, D.W., Heath-Chiozzi, M., Danner, S., Cohen, C., Kravcik, S., Maurath, C., Sun, E., Henry, D., Potthoff, A., Leonard, J.M. and the advanced HIV disease ritonavir study group, 1998. Prolongation of life and prevention of AIDS complications in a randomized placebo-controlled clinical trial of ritonavir in patients with advanced HIV disease. Lancet 351, 543-549.
7. Cameron, D.W., Japour, A., Mellore, J., Farthing, C., Cohen, C., Markowitz, M., Poretz, D., Follansbee, S., Ho, D., Mahon, D.M., Berg, J., Nieves, J., Xu, Y., Rode, R., Salgo, M., Leonard, J., Sun, E., 1998b. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor naive patients in year two of follow-up. 5th Conference on Retroviruses and Opportunistic Infections. Abstract 388, IL.
8. Carrillo, A., Sham, H., Norbeck, D., Kempf, D., Kohlbrenner, W., Plattner, J.J., Leonard, J., Molla, A., 1997. Mutation in the proteolytic sites is required for the growth of mutant HIV selected by ABT-378, a new HIV protease inhibitor. Abstract I 116. 37th ICAAC, Toronto, Canada.
9. Cavert W., Notermans D.W., Staskus K., Wietgrefe S.W., Zupancic M., Gebhard K., Henry K., Zhang Z.-Q., Mills R., McDade H., Goudsmit J., Danner S.A., Haase A.T. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 276:1997;960-964.
10. Chiba M., Hensleigh M., Nishime J.A., Balani S.K., Lin J.H. Role of cytochrome P-450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug. Metab. Disp. 24:1996;307-314.
11. Chong K.-T., Pagano P.J. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother. 41:1997;2367-2373.
12. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acd. Sci. U.S.A. 94:1997;13193-13197.
13. Coffin J.M. HIV population dynamics in vivo: implication for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
14. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Deutsch P.J., Holder D.J., Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London). 374:1995;569-571.
15. Connick, E., Lederman, M., Kotzin, B., Wade, M., Spritzler, J., Kuritzkes, D., St. Clair, M., Kessler, H., Roe, J., Fox, L., Martinez, A., Heath-Chiozzi, M., Rousseau, F., Landay, E., ACTG 315 protocol team, 1998. Immunologic effects of 48 weeks of AZT/3TC/ritonavir. Abstract LB14. 5th Conference on Retroviruses and Opportunistic Infections, IL.
16. Danner, S.A., 1996. Immediate versus delayed triple therapy with ritonavir, AZT and 3TC. Program and abstracts of the International Congress on Drug Therapy in HIV Infection. Birmingham, UK.
17. Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V., Aguado A.G., Garcia deLamos J., Delgado R., Borleffs J.C.C., Hsu A., Valdes J., Boucher C.A.B., Cooper D.A. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1protease. New Engl. J. Med. 333:1995;1528-1533.
18. Darke P.L., Nutt R.F., Brady S.F., Garsky V.M., Ciccarone T.M., Leu C.-T., Lumma P.K., Freidinger R.M., Veber D.F., Sigal I.S. HIV-1 protease specificityide cleavage is sufficient for processing of gag and pol polyprotein. Biochem. Biophys. Res. Commun. 156:1988;297-303.
19. Deeks, S., Grant, R., Horton, C., Simmonds, N., Follansbee, S., Eastman, S., 1997. Virologic effect of ritonavir (RTV) plus saquinavir (SQV) in subjects who have failed indinavir (IDV). 37th ICAAC, Abstract I-205, Toronto, Canada.
20. De Pasquale, M.P., Murphy, R., Gulick, R., Smeaton, L., Sommadossi, J.-P., Degruttola, V., Calindo, A., Kuritzkes, D., Sutton, L., Savara, A., D'Aquila, R., 1998. Mutations selected in HIV plasma RNA during 141W94 therapy. 5th Conference on Retroviruses and Opportunistic Infections. Abstract 406a, IL.
21. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:1996;3763-3769.
22. Dubouck C. The HIV protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses. 8:1992;153-160.
23. Eberle J., Bechowsky B., Rose D., Hauser U., Von Der Helm K., Gurtler L., Nitschko H. Resistance of HIV type 1 to proteinase inhibitor Ro31-8959. AIDS Res. Hum. Retroviruses. 11:1995;671-675.
24. Farthing, C., Japour, A., Cohen, C., Cameron, W., Follansbee, S., Markowitz, M., Mellors, J., Poretz, D., Ho, D., Mahon, D.M., Berg, J., Nieves, J., Xu, Y., Rode, R., Salgo, M., Leonard, J., Sun, E., 1997. Cerebrospinal fluid and plasma HIV RNA suppression with ritonavir-saquinavir in protease inhibitor naive patients. Abstract LB-3. 37th ICAAC, Toronto, Canada.
25. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
26. Fiske, W.D., Mayers, D., Wagner, K., Riddler, S., Drusano, G., Stein, D., Bach, M., Havlir, D., Kahn, J. 1997. Pharmacokinetics of DNP 266 and indinavir multiple oral doses in HIV-1 infected individuals. Abstract 568. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC.
27. Gallant, J.E., Heath-Chiozzi, M., Raines, C., Anderson, R., Katz, T.K., Fields, C., Jackson, J.B., Flexner C., 1998. Safety and efficacy of nelfinavir-ritonavir combination therapy. 5th Conference on Retroviruses and Opportunistic Infections. Abstract 394a, IL.
28. Gallicano, K., Sahai, J., Kravcik, S., Seguin, I., Bristow, N., Cameron, D.W., 1998. Nelfinavir increases plasma exposure of saquinavir in hard get capsule in HIV+ Patients. Abstract 353. 5th Conference on Retroviruses and Opportunistic Infections, IL.
29. Gulick R., Mellors J., Havlir D., Eron J., Gonzalez C., McMahon D., Richman D., Valentine F., Jonas L., Meibohm A., Emini E., Chodakewitz J. Treatment with indinavir, zidovudine, and lamivudine in adaults with human immunodeficience virus infection and prior antiretroviral therapy. New Engl. J. Med. 337:1997;734-739.
30. Gulnik S.V., Suvorov L.I., Liu B., Yu B., Anderson B., Mitsuya H., Erickson J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry. 34:1995;9282-9287.
31. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron J.J., Feinberg J.E., Balfour H.H., Deyton L.R., Chodakewitz J.A., Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl. J. Med. 337:1997;725-733.
32. Hertogs, K., Mellors, J.W., Schel, P., Van Cauwenberghe, A., Larder, B., Kemp, S., Miller, V., Stasewski, S., Conant, M., Pauwels, R., 1998. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV isolates. Abstract 395. 5th Conference on Retroviruses and Opportunistic Infections, IL.
33. Ho D.D., Toyoshima T., Kempf D.J., Norbeck D., Chen C.-M., Wideburg N.E., Burt S.K., Erickson J.W., Singh M.K. Characterization of HIV-variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:1994;2016-2020.
34. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infections. Nature (London). 373:1995;123-126.
35. Hodge C.N., Aldrich P.E., Bacheler L.T., Chang C.-H., Eyermann C.J., Garber S., Grubb M., Jackkson D.A., Jadhab P.K., Korant B., Lam P.Y.S., Maurin M.B., Meek J.L., Otto M.J., Rayner M.M., Reid C., Sharpe T.R., Shum L., Winslow D.L., erickson-Vitanen S. Improved cyclic urea inhibiyors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem. Biol. 3:1996;301-314.
36. Holland J.J., Torre De La J.C., Steinhauer D.A. RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 176:1992;1-20.
37. Hsu, A., Granneman, G.R., Japour, A., cao, G., Locke, C., Carothers, L., Dennis, S., El-Shourbagy, T., Leonard, J., 1997. Evaluation of potential ritonavir and indinavir combination BID regimen. Abstract A-57. 37th ICAAC, Toronto, Canada.
38. Jacobsen H., Haenggi M., Ott M., Duncan I.B., Vella S., Mous J. In vivo resistance to HIV protease inhibitor saquinavir-an update. AIDS Res. Hum. Retrovirues. 11:1995;S169.
39. Jacobsen H., Yasargil K., Winslow D.L., Craig J.C., Krohn A., Duncan I.B., Mous J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteae inhibitor Ro 31-8959. Virology. 206:1995;527-534.
40. Jadhav P.K., Francis P.A., Woerner F.J., Chang C.-H., Garber S.S., Anton E.D., Bacheler L.T. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40:1997;181-191.
41. Kaufmann, G., Duncombe, C., Beveridge, A., Chuah, J., Carr, A., Cunningham, P., Cooper, D.A., 1997. Efficacy of a four drug combination therapy including two protease inhibitors in patients with advanced HIV-1 illness. Abstract I-200, 37th ICAAC, Toronto, Canada.
42. Kempf D.J., Marsh K.C., Kumar G., Rodrigues A.D., Denissen J.F., McDonald E., Kukulka M.J., Hsu A., Granneman G.R., Baroldi P.A., Sun E., Pizzuti D., Plattner J.J., Norbeck D.W., Leonard J.M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:1997;654-660.
43. Kempf, D.J., Rode, R.A., Xu, Y., Sun, E., Heath-Chiozzi, M.E., Valdes, J., Japour, A.J., Danner, S., Boucher, C., Molla, A., Leonard, J.M., 1998. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12, F9-F14.
44. Kerr, B., Lee, C., Yuen, G., Anderson, R., Daniels, R., Grettenberger, H., Liang, B.-H., Quart, B., Sandoval, T., Shetty, B., Wu, E., Zhang, K., 1997. Overview of in vitro and in vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor. Abstract 373. 4th Conference on Retrovirus and Opportunistic Infections, Washington, DC.
45. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A.F., Scolnick E.M., Sigal I.S. Active human immunodefiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA. 85:1988;4686-4690.
46. Korneyeva, M., Chernyvskiy, T., Norbeck, D., Sham, H., Kempf, D., Kohlbrenner, W., Plattner, J.J., Leonardf, J., Molla, A., 1997. Virological Evaluation of Ritonavir-Resistant Virus to the HIV Protease Inhibitor ABT-378. Abstract-212. 4th Conference on Retrovirus and opportunistic Infections, Washington DC.
47. Kumar G.N., Rodrigues A.D., Buko A., Denissen J.F. Cytochrome P-450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;423-431.
48. Kravcik, S., Sahai, J., Kerr, B., Anderson, R., Buss, N., Seguin, I., Bristow, N., Farnsworth, A., Salgo, M., 1997. Nelfinavir mesylate increases saquinavir-soft gel capsule exposure in HIV+ patients. Abstract-371. 4th Conference on Retrovirus and Opportunistic Infections, Washington, DC.
49. Lal, R., Hsu, A., Grannemen, G.R., El-Shourbagy, T., Johnson, M., Law, W., Manning, L., Japour, A., Sun, E., 1998. Multi dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir. 5th Conference on Retroviruses and Opportunistic Infections. Abstract 647, IL.
50. Lambert D.M., Petteway S.R., McDanal C.E., Hart T.K., Leary J.J., Dreyer G.B., Meek T.D., Bergelski P.J., Bolognesi D.P., Metcalf B.W., Methews T.J. Antimicrob. Agents Chemother. 36:1992;982-988.
51. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodefiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 60:1995;5087-5094.
52. Markowitz, M., Cao, Y., Hurley, A., O'Donovan, R., Peterkin, J., Anderson, B., Smiley, L., Keller, A., Johnson, P., Johnson, D., Ho, D.D., 1996. Triple therapy with AZT, 3TC in combimnation with nelfinavir mesylate in 12 antiretroviral naive subjects chronically infected with HIV. Abstract LB-B6031. Program and abstracts of the XI International Conferences on AIDS. Vancouver, BC, Canada.
53. Markowitz M., Mo H., Kempf D.J., Norbeck D.W., Bhat T.N., Erickson J.W., Ho D.D. Selection and analysis of human immunodeficiency virus type a variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:1995;701-706.
54. Markowitz M., Saag M., Powderly W.G., Hurley A.M., Hsu A., Valdes J.M., Henry D., Sattler M., Marca A.L., Leonard J.M., Ho D.D. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engl. J. Med. 333:1995;1534-1539.
55. Marsh, K., McDonald, E., Sham, H., Kempf, D., Norbeck, D., 1997. Enhancement of ABT-378 pharmacokinetics when administered in combination with ritonavir. Abstract 210. 4th Conference on Retrovirus and opportunistic Infections, Washington DC.
56. Mathez D., Bagnarelli P., Gorin I., Katalama C., Pialoux G., Saimot G., Tubiana P., De Truchis P., Chauvin J.-P., Mills R., Rode R., Clementi M., Leibowitch J. Reductions in viral load and increases in T-lymphocytes in treatment naive patients with advanced HIV infection, treated with ritonavir, zidovudine, and zalcitabine triple therapy. Antiviral Ther. 2(3):1997;175-183.
57. Mayers, D., Riddler, S., Bach, M., Stein, D., Havlir, M.D., Kahn, J., Ruiz, N., Labriola, D.F., DMP 266 clinical development team, 1997. Durable clinical anti-HIV activity and tolerability for DMP 266 in combination with indinavir at 24 weeks. Abstract I-175. 37th ICAAC, Toronto, Canada.
58. McCrea, J., Woolf, E., Sterrett, A., Matthews, C., Deutsch, P., Yeh, K.C., Waldman, S., Bjornsson, T., 1996. Effects of ketoconazole and other P-450 inhibitors on the pharmacokinetics of indinavir. Abstract PPDM 8370. American Association of Pharmacological Scientists, p. 485.
59. McCrea, J., Buss, N., Stone, J., Carides, A., Dru, J., Stewart, F., Brown, A., Yeh, K., Salgo, M., Waldman, S., Deutsch, P., 1997. Indinavir-saquinavir single dose pharmacokinetic study. Abstract 608. 4th Conference on Retrovirus and Opportunistic Infections, Washington, DC.
60. Miller, V., Hertogs, K., Bethune, M.-P., Pauwels, R., Ivens, T., Azijn, H., Schlecht, C., Nolde, B., Sturmer, M., Morgenstern, B., Kortenbusch, M., Staszewski, S., 1997. Incidence of HIV-1 resistance and cross-resistance to protease inhibitors after indinavir failure: impact on subsequent ritonavir/saquinavir combination therapy. Abstract 81, Sixth International Workshop on HIV drug resistance, treatment strategies and eradication, St. Petersburg, FL.
61. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.-M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G.R., Ho D.D., Boucher C.A.B., Leonard J.M., Norbeck D.W., Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:1996;760-766.
62. Molla, A., Vasavanonda, S., Denissen, J., Kumar, G., Grabowski, B., Sham, H., Norbeck, D., Kempf, D., Kohlbrenner, W., Plattner, J.J., Leonard, J., 1997. Effect of Human Serum Proteins on the Antiretroviral Activity of Ritonavir and ABT-378, Potent Inhibitors of HIV Protease. Abstract 213. 4th Conference on Retrovirus and opportunistic Infections, Washington DC.
63. Mueller, B.U., Zuckerman, J., Nelson, R.P., Sleasman, J., Saulis, R., Higham, C., Brouwers, P., Janelevich, S., Jarosinski, P., Sei, S., Serchuck, L.K., Wood, L.V., Zeichner, S., Heath-Chiozzi, M., Pizzuti, D., Pizzo, P.A., 1997. Update on the pediatric phase I/II study of the protease inhibitor ritonavir (ABT-538). Abstract 722. 4th Conference on Retrovirus and Opportunistic Infections, Washington, DC.
64. Murphy, R., Gagnier, P., Lamson, M., Dusek, A., Ju, W., Hsu, A., 1997. Effect of nevirapine on pharmacokinetics of indiavir, and ritonavir in HIV-1 patients. 4th conferences on retroviruses and opportunistic infections. Abstract 374, Washington, DC.
65. Navia M.A., Fitzgerald P.M.D., McKeever B.M., Leu C.T., Heimbach J.C., Herber W.K., Sigal I.K.S., Darke P.L., Springer J.P. Three dimensional structure of the aspartyl protease from human immunodefiency virus HIV-1. Nature. 337:1989;515-621.
66. Opravil, M., on behalf of the SPICE study team, 1998. Study of protease inhibitor combination in Europe (SPICE): saquinavir soft gel capsule and nelfinavir in HIV infected individuals. 5th Conference on Retroviruses and Opportunistic Infections. Abstract 394b, IL.
67. Partaledis J.A., Yamaguchi K., Tisdale M., Blair E.E., Falcione C., Maschera B., Myers R.E., Pazhanisamy S., Futer O., Cullinan A.B., Stuver C.M., Byrn R.A., Livingston D.J. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. Antimicrob. Agents Chemother. 69:1995;5228-5235.
68. Patick A.K., Mo H., Markowitz M., Appelt K., Wu B., Musick L., Kalish V., Kaldor S., Reich S., Ho D., Webber S. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicro. Agents Chemother. 40:1996;292-297.
69. Patick, A.K., Kuritzkes, D., Johnson, V.A., Shugarts, D., Bakhtiari, M., Potts, K.E., Farnsworth, A., Anderson, R., Koel, J.L., Hazelwood, J.D., Nail, C.D., Duran, M., Markowitz, M., Ho, D., Richman, D., 1997. Genotypic and phenotypic analyses of HIV-1 variants isolated from patients treated with nelfinavir and other protease inhibitors. Abstract 18, Sixth International Workshop on HIV drug resistance, treatment strategies and eradication, St. Petersburg, FL.
70. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
71. Piscitelli, S., Vogel, S., Sadler, B., Fiske, W., Metcalf, J., Masur, H., Falloon, J., 1998. Effect of efavirenz (DMP266) on the pharmacokinetics of 141W94 in HIV-infected patients. Abstract 346. 5th Conference on Retroviruses and Opportunistic Infections, IL.
72. Polk, R.E., Israel, D.S., Pastor, A., Sadler, B.M., Chittick, G.E., Symonds, W.T., Crouch, M., Gouldin, W., Lou, Y., Rawls, C., Bye, A., 1997. Pharmacokinetic interaction between ketoconazol and the HIV protease inhibitor 141W94 after single dose administration to normal volunteers. Abstract A-61. 37th ICAAC, Toronto, Canada.
73. Polk, R.E., Israel, D.S., Pastor, A., Sadler, B.M., Chittick, G.E., Symonds, W.T., Brophy, D., Kristoff, D., Lou, Y., Bye, A., 1998. Pharmacokjinetic interaction between 141W94 and rifabutin and rifampin after multiple dose administration. Abstract 340. 5th Conference on Retroviruses and Opportunistic Infections, IL.
74. Poppe S.M., Slade D.E., Chong K.T., Hinshaw R.R., Pagano P.J., Markowitz M., Ho D.D., Mo H., Gorman III R.R., Dueweke T.J., Thaisrivongs S., Tarpley W.G. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicro. Agents Chemother. 41:1997;1058-1063.
75. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shih C.-K., Myers M., Griffin J.J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
76. Sadler, B.B., Eron, J., Wakeford, J., Pagano, G., Rawls, C., Mccrea, J., Mazina, K., Deutsch, P.J., 1997. Pharmacokinetics of 141W94 and indinavir after single-dose administration in HIV positive volunteers. Abstract A-56, 37th ICAAC, Toronto, Canada.
77. Sampson, M., Torres, R.A., Stein, A.J., Cochrane, J.M., Taylor, B., Mcintyre, K., Shay, W., Barr, M.R., Fischer, L., 1997. Ritonavir-saquinavir combination treatment in protease inhibitor experienced patients with advanced HIV disease. 37th ICAAC, Abstract I-104, Toronto, Canada.
78. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. Antiviral News. 4:1996;95-107.
79. Schapiro J.M., Winters M.A., Stewart F., Efron B., Norris J., Kozal M.J., Merigan T.C. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Int. Med. 124:1996;1039-1050.
80. Schapiro, J.M., Winters, M.A., Vierra, M., Jacobson, H., Mous, J., Merigan, T.C., 1996b. Resistance mutations in patients receiving saquinavir: simultaneous appearance in lymph nodes, peripheral blood mononuclears (PBM) and plasma. Abstract of the Fifth International workshop, Whistler, Canada, p. 28.
81. Schock H.B., Garsky V.M., Kuo L.C. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials - compensatory modulations of binding and activity. J. Biol. Chem. 271:1996;31957-31963.
82. Schmit J.-C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., Vandamme A.-M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with protease inhibitor ritonavir (ABT-538). AIDS. 10:1996;995-999.
83. Sham, H., Kempf, D., Molla, A., Marsh, K., Betebenner, D., Chen, X., Rosenbrook, W., Wideburg, N., Chen, C., Kati, W., Kumar, G., Korneyeva, M., Vasavanonda, S., McDonald, E., Saldivar, A., Chernyavskiy, T., Carrillo, A., Lyons, N., Park, C., Stewart, K., Plattner, J.J., Norbeck, D., 1997. Design, synthesis and biological properties of ABT-378, ahighly potent HIV protease inhibitor. Abstract 1, 4th Conference on Retrovirus and opportunistic Infections, Washington DC.
84. Slater, L., on behalf of the NV15355 study group, 1998. Activity of new formulation of saquinavir in combination with two nucleosides in treatment naive patients. Abstract 368. 5th Conference on Retroviruses and Opportunistic Infections, IL.
85. Smith, T., Swanstrom, R., 1996. Selection for high level resistance to HIV-1 protease inhibitors used in pairs. Abstract of the Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, p. 20.
86. Stein D.S., Fish D.G., Bilello J.A., Preston S.L., Martineau G.L., Drusano G.L. A 24-week open-label phaseI/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 10:1996;485-492.
87. Thaisrivongs S., Skulnick H.I., Turner S.R., Strohbach J.W., Tommasi R.A., Johnson P.D., Aristoff P.A., Judge T.M., Gammill R.B., Morris J.K., Romines K.R., Chrusciel R.A., Hinshaw R.R., Chong K.T., Tarpley W.G., Poppe S.M., Slade D.E., Lynn J.C., Horng M.-M., Tomichj P.K., Seest E.P., Dolak L.A., Howe W.J., Howard G.M., Schwende F.J., Toth L.N., Padbury G.E., Wilson G.J., Shiou L., Zipp G.L., Wilson K.F., Rush B.D., Ruwart M.J., Koeplinger K.A., Zhao Z., Cole S., Zaya R.M., Kakuk T.J., Janakiraman M.N., Watenpaugh K.D. Structure based design of HIV protease inhibitor s: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non peptidic inhibitors. J. Med. Chem. 39:1996;4349-4353.
88. Tisdale, M., Meyers, R.E., Blair, E., Kohli, A., Kemp, S.D., Larder, B.A., 1995. In vitro studies support combination therapy with HIV protease inhibitors. Fourth International Workshop on HIV drug Resistance, Sardinia, Italy, p. 61.
89. Tisdale, M., Myers, R., Najera, I., Kohli, A., Kemp S., Larder, B.A., 1996. Analysis of resistance interactions with 141W94 (VX-478) and other HIV protease inhibitors. Abstract of the Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, p. 27.
90. Tozser J., Blahah I., Copeland T.D., Wondrak E.M., Oroszlan S. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in gag and gag-pol polyprotein. FEBS Lett. 281:1991;77-80.
91. Vasudevachari M.B., Zhang Y.-M., Imachi H., Imachi T., Falloon J., Salzman N.P. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type-1 isolates from patients and rapid screening procedure for their detection. Antimicro. Agents Chemother. 40:1996;2535-2541.
92. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., Saag M.S., Shaw G.M. Viral dynamics in human immunodefiency virus type 1 infection. Nature (London). 373:1995;117-122.
93. Winchell, G.A., McCrea, J.B., Carides, A., Kusma, S.E., Chiou, R., Deutsch, P., Yeh, K.C. Waldman, S., Bjornsson, T.D., 1997. Pharmacokinetic interaction between indinavir and rifabutin. Abstract PI-66. American Association Clinical Pharmacolgical Therapists, p. 153.
94. Wlodawer A., Miller M., Jaskolski M., Sathyanarayana B.K., Baldwin E., Weber I.T., Selk L.M., Clawson L., Schneider J., Kent S.B.H. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-a protease. Science. 245:1989;616-621.
95. Wong J.K., Hezareh M., Gunthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
96. Woolley, J., Studenberg, S., Boehlert, C., Bowers, G., Sinhababu, A., Adams, P., 1997. Cytochrome P-450 isozyme induction, inhibition and metabolism studies with HIV protease inhibitor, 141W94. Abstract A60. 37th ICAAC, Toronto, Canada.
97. Yuen G.J., Anderson R., Sandoval T., Wu E., Shetty B.V., Kerr B.M. The pharmacokinetics of nelfinavir administered alone and with rifampin in healthy volunteers (Abstract PI-40). Clin. Pharmacol. Ther. 61:1997;147.
98. Zhang Y., Imamichi H., Imamichi T., Lane C.H., Falloon J., Vasudevachari M.B., Salzman N.P. Drug resistance dirung indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J. Virol. 71:1997;67662-67667.